Pharma BD Deal Intelligence
A $4B eight-year extension of Bristol-Myers Squibb's neurodegeneration collaboration with Evotec, built on their 2016 partnership around clinical-stage asset EVT8683. A long-horizon co-development bet on neurodegenerative disease research rather than a near-term revenue deal.
Evotec and Bristol Myers Squibb progress their strategic partnership in neurodegeneration, leveraging Evotec's modality-agnostic precision medicine platforms…
Evotec and Bristol Myers Squibb advance their neuroscience partnership, with the first program EVT8683 progressing into clinical Phase I following successful…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
BMS extended and expanded its strategic neurodegeneration partnership with Evotec for 8 additional years, building on their 2016 collaboration including clinical-stage EVT8683.
6.7M US cases/yr · $17.7B Global Market · <10% Patients with Disease-Modifying Therapy
Neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and frontotemporal dementia represent one of the largest unmet needs in medicine. Despite billions invested, most clinical programs have failed, and only a handful of disease-modifying therapies have reached the market.
The BMS-Evotec partnership, originally signed in 2016 and expanded to $4B in 2023, uses Evotec's iPSC-based drug discovery platform to identify disease-modifying targets. Lead candidate BMS-986419 entered Phase II in 2024. Competitors include Biogen/Eisai (Leqembi), Lilly (donanemab), and Roche in the broader neurodegeneration space.
BMS extended neurodegeneration collaboration 8 years. $50M upfront, up to $4B total.
EVT8683 (BMS-986419) completed Phase 1. BMS paid $25M milestone. Part of Bristol-Myers Squibb Co.'s $4B deal to acquire Evotec SE.
Longest-running strategic neuro partnership (since 2016). Phase 1 complete. Milestones flowing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Evotec SE (this deal) | 2023 | $4.0B | 66 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Neurology deals